CXCL13 Signaling in the Tumor Microenvironment
- 22 July 2021
- book chapter
- research article
- Published by Springer Science and Business Media LLC
- Vol. 1302, 71-90
- https://doi.org/10.1007/978-3-030-62658-7_6
Abstract
Chemokines have emerged as important players in tumorigenic process. An extensive body of literature generated over the last two or three decades strongly implicate abnormally activated or functionally disrupted chemokine signaling in liaising most—if not all—hallmark processes of cancer. It is well-known that chemokine signaling networks within the tumor microenvironment are highly versatile and context-dependent: exert both pro-tumoral and antitumoral activities. The C-X-C motif chemokine ligand 13 (CXCL13), and its cognate receptor CXCR5, represents an emerging example of chemokine signaling axes, which express the ability to modulate tumor growth and progression in either way. Collateral evidence indicate that CXCL13-CXCR5 axis may directly modulate tumor growth by inducing proliferation of cancer cells, as well as promoting invasive phenotypes and preventing their apoptosis. In addition, CXCL13-CXCR5 axis may also indirectly modulate tumor growth by regulating noncancerous cells, particularly the immune cells, within the tumor microenvironment. Here, we review the role of CXCL13, together with CXCR5, in the human tumor microenvironment. We first elaborate their patterns of expression, regulation, and biological functions in normal physiology. We then consider how their aberrant activity, as a result of differential overexpression or co-expression, may directly or indirectly modulate the growth of tumors through effects on both cancerous and noncancerous cells.Keywords
This publication has 122 references indexed in Scilit:
- Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5Molecular Cancer, 2013
- CD4+ follicular helper T cell infiltration predicts breast cancer survivalJCI Insight, 2013
- Regulation of TH2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cellsNature Immunology, 2012
- Tumor immunosurveillance in human cancersCancer and Metastasis Reviews, 2011
- PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cellsMolecular Cancer, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic miceInternational Journal of Cancer, 2009
- Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesionCancer Letters, 2009
- Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell linesInternational Journal of Cancer, 2009
- Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patientsBritish Journal of Cancer, 2008